The announcement of presenting additional data from a significant trial at a major industry event typically generates positive investor sentiment, leading to an increase in stock value. Given the specific mention of KIO-301 in retinitis pigmentosa, a condition with limited treatment options, this news is likely to be particularly well-received by the market.